The board of directors of ClouDr Group Limited announced that on December 29, 2023, the Group completed the application for registration as a medical device in the People's Republic of China in respect of ClouDT-01, a self-developed diabetes-related digital therapeutics product. ClouDT-01 is a cutting-edge digital therapeutics product for the management of diabetes patients with efficacy. By leveraging the Group's advanced digital medical artificial intelligence foundation model, comprehensive diabetes service management database, and extensive diabetes clinical experience, ClouDT-01 provides sensitivity analysis of related indicators for vital diseases, serving both clinical professionals and patients.

It facilitates real-time, dynamic, and comprehensive diabetes management, and further benefits diabetes patients clinically. The Company is committed to developing excellence-driven digital healthcare services and products for the improvement of the accessibility and affordability of healthcare services.